Introduction: Psoriasis is a chronic condition whose therapeutic armamentarium is increasingly being discussed, particularly when compared to past decades. The use of biologic agents has profoundly changed the history of this disease, as well as the management of psoriatic patients. Due to the enormous interest in psoriasis, as demonstrated within the scientific community and pharmaceuticals, new therapeutic targets have been identified and novel patented therapeutics are being tested.
Article highlights
• Although biologic therapies profoundly modified the management of psoriasis, still unmet needs remain.
• Novel patented drugs are being tested for the treatment of psoriasis, both small molecule agents and biologicals.
• Intracellular signaling molecules (JAK-STAT, PDE4, A3 adenosine receptor, S1P, and aka activating protein 1) as well as soluble mediators (i.e. IL-23, IL-17, VEGF-A), receptors (i.e., IL-17R), and surface costimulator molecules (i.e., CD6) have been recognized as therapeutic targets.
• Conceptually, bispecific agents could represent a revolutionary approach as current biologic therapeutics target one single molecule.
• The development of more selective and more effective drugs that maintain very high standards of safety, compared to previously approved biologic agents, is the result of an increased understanding in the psoriasis pathogenic mechanism.
Introduction
Psoriasis is a chronic skin disorder whose pathogenic mechanism has been deeply investigated in the last three decades, revealing a crucial role of both adaptive and innate immunity. The immune activation may be triggered by various mechanisms including the presence of self-molecules identified as auto-antigens by autoreactive T cells, both CD4+ and CD8+ T cells [1] . However, early steps of the pathogenesis might involve plasmacytoid and myeloid dendritic cells (pDCs and mDCs, respectively) activated by self-DNA or RNA combined with LL-37 or by chemerin [2] [3] [4] [5] . Psoriasis skin inflammation is driven by multiple immune circuits amplified by keratinocytes that recruit T cells, neutrophils, DCs, and other immune cells, producing chemokines and AMPs acting as chemoattractans.
Though key-cytokines such as IL-22, TNF±, and IFN-³ drive pathogenic pathways, which resulted upregulated in psoriasis, mounting evidence has proved the crucial role of the IL-23/IL-17 axis [6] .
In this setting, multiple therapeutic targets may be identified: chemokines and their receptors, cytokines and their receptors, adhesion molecules, cell surface antigens, transcription factors, and other intracellular signal transducers.
Psoriasis pathogenesis: identification of selective therapeutic targets

Key cells contributing to psoriasis: T cells
Various subtypes of T cells abundantly infiltrate lesional psoriatic skin including ³´+ T cells and CD4+ T cells, localized within the dermis, and CD8+ T cells infiltrating the epidermis [7] [8] [9] . Beside activated resident T cells, the psoriatic plaque includes migrating T cells from the blood circulation. These cells reach lesional skin because of the interaction between leukocyte function-associated antigen-1 (LFA-1), a member of ² 2 integrin family, and intracellular adhesion molecule-1 (ICAM-1), that responses by converting cytokine signals into genomic responses and, thus, regulating immune cell proliferation and differentiation [18, 19] .
Overall, JAK tyrosine kinases consist in a family of four non-receptor tyrosine kinases, namely JAK1, JAK2, JAK3 and Tyk2 that act in pairs in the intracytoplasmatic portion of the cytokine receptor. JAK signaling is conventionally transduced to an array of transcription activators, the STAT family, that includes 7 members: STAT1, STAT2, STAT3, STAT4, STAT5A, STAT5B and STAT6 [20] .
Because several cytokines such as IFN-±, IFN-³ , IL-2, IL-6, IL-12, IL-15, IL-19, IL-20, IL-22, IL-23, and IL-24 involved in psoriasis pathogenesis act through JAK/STAT signaling pathways, its blockade has been recently proved beneficial in clearing psoriasis [21] .
Another highly expressed intracellular enzyme is PDE-4 that is found in activated inflammatory cells (i.e. T cells, DCs) as well as skin tissue cells (i.e., keratinocytes) [22] . Additionally, activated lymphocytes express S1P that is a sphingolipid required to exit the lymphoid tissue and enter the bloodstream via a chemotactic gradient [23] .
In this crosstalk involving immune and tissue cells, a plethora of therapeutic targets may be identified for emerging, recently-patented drugs. Particularly, key-cytokines, namely TNF± and IL-17, demonstrated to be crucial in mediating the most relevant inflammatory circuits; and intracellular signaling pathway transducers (i.e., JAK-STAT, PDE4, and S1P) are involved in the pathways driving inflammation and/or proliferation. In this review, we will report patent drugs including small molecules and monoclonal antibodies that are being developed and that may represent promising antipsoriatic therapies in the future.
Small molecules
The so-called small molecule drugs are characterized by low molecular size.
Compared to biologic therapy, their production is less expensive and allow an oral or topical administration. These therapies are able to neutralize the effects of cytokines or cytokine receptors blocking intracellular targets such as transcriptional factors or enzymes. Moreover, these products could alleviate many of the challenges that are associated with biologics, namely price, difficulty in production, clinical contraindications, method of administration, and difficulty in producing a significantly less expensive counterpart when patents expire.
Several group of small molecules are under evaluation for the treatment of psoriasis including: 1) JAK inhibitors, 2) the PDE 4 inhibitors, 3) A3 adenosine receptor agonists, 4) TNF± inhibitors, 5) S1P agonist, and 6) aka activating protein 1 (AP-1).
JAK inhibitors
The JAK protein tyrosine kinase family is constituted by cytoplasmic PTKs that play a pivotal role in cytokine signal transduction pathways through association with various cytokine receptors by activation of the latent forms of STATs involved in the pathogenesis of psoriasis.
Protein kinases like JAKs are enzymes, which transfer phosphate groups from adenosine triphosphate (ATP) or guanosine triphosphate to hydroxyl groups of amino acids of their substrates. Tyrosine kinases phosphorylate tyrosine residues and blocking their enzymatic activity has proved to be a successful strategy [24] . JAK1 is involved in the activation of IFN-³ , IL-6 and IL-10 receptors. JAK2 primarily associates with hematopoietic receptors, but also with IL-12 and IL-23 receptors.
JAK3 is the most specific type as it acts only with receptors that contain the common ³ chain (IL-2, IL-4, IL-7, IL-9, IL-15, and IL-21), whose signals are crucial for lymphocyte activation, proliferation and function [25] [26] . Because JAK3 is crucial in transducing signals of relevant pathogenic cytokines, such as IL-23, the development of small molecule drugs targeting this kinase were thought to have a therapeutic relevance, as subsequently demonstrated in clinical trial phases.
Tofacitinib is an inhibitor of the JAK1 and JAK3 signaling pathway and it is one of the first JAK inhibitors used in humans. It has been reported to be a safe and effective therapy for ulcerative colitis [26, 27] and rheumatoid arthritis [28, 29] and results of the phase II and III studies on psoriasis have been published [30, 31] . Due to their small molecular size, tofacitinib has also been studied as topical treatment for psoriasis. In a vehicle-controlled phase IIa trial studying a topical tofacitinib ointment formulation, Ports et al. reported the psoriasis patients treated with tofacitinib 2% ointment 1 BID present an improvement in the target plaque severity score at week 4 [32] .
Another JAK inhibitor is ruxolitinib that preferentially inhibits JAK1 and JAK2 and it has been firstly investigated as topical formulation (INCB018424, Incyte) for use in psoriasis [33] . A Phase 2a trial comparing topical INCB018424 0.5%, 1% and 1.5%
cream in a double-blind, vehicle-controlled trial was shown to be safe and effective with improvement in total lesion score, PGA and PASI [34] .
There are additional JAK inhibitors undergoing investigation for the treatment of moderate-to-severe psoriasis [35] , such as baricitinib (INCB-28050/LY3009104), a JAK1 and JAK3 inhibitor, that is being examined in a phase IIb dose ranging study [36] .
PDE4 inhibitors
Apremilast is an orally available, specific inhibitor of PDE-4 that works intracellularly 
A 3 adenosine receptor agonists
A 3 adenosine receptor agonists are (AAr) G protein-coupled receptors that are involved in a variety of intracellular signaling pathways and physiological functions.
The natural ligand of AAr receptors is adenosine. AArs are highly expressed in peripheral blood mononuclear cells isolated from patients with psoriasis and the AAr activation with a specific agonist (CF101) downregulates the nuclear factor-º B signaling pathway, inhibits the proliferation of specific autoreactive T lymphocytes, and induces apoptosis of inflammatory cells [45] . These effects result in the downregulation of proinflammatory cytokines, such as TNF±, IL-6, and IL-12 [46] .
In a Phase II, multicentre, dose-ranging study, patients with moderate-to-severe plaque-type psoriasis were treated with CF101 (1 mg, 2 mg, or 4 mg) or placebo administered orally BID for 12 weeks. In the 2 mg CF101-treated group, a progressive improvement in the mean change from baseline in PASI versus placebo throughout the study period was observed, with a statistically significant difference at weeks 8 and 12. In this group, 35.3% of the patients achieved PASI50 response; a higher response rate was not achieved. Side effects reported were considered mild [47] .
Patented biologic agents
The introduction of biologic agents profoundly changed the management of psoriasis and its therapeutic algorithm, particularly in the long-term treatment. agent, ustekinumab, has also been approved for the treatment of psoriasis, and other biologic agents targeting the same pathogenic axis will be marketed.
Anti-IL23 agents
Besides anti-TNF± inhibitors, new agents targeting other steps in the pathogenic cascade of psoriasis have been developed. IL-23 is a central cytokine to the pathogenesis of psoriasis, its main immunologic role is the involvement in the differentiation process of naïve Th cells into Th17. IL-23 might be targeted by: 1) antip40 agents such as ustekinumab, approved for the treatment of plaque-type psoriasis and psoriatic arthritis, and briakinumab (abt-874), another fully humanized antibody that reached a pre-registration status but its development has been discontinued because of the increased incidence in US of major cardiovascular events occurring in briakinumab-treated patients; 2) anti-p19 agents like tildrakizumab (MK-3222), a fully human IgG1 antibody (Merck) that is in a more advanced status of development compared to the other three agents; and 3) IL-23R-antagonists, which are currently being tested in preclinical studies, although no information yet exists regarding their biochemical structure, the status of development or pharmacokinetics and pharmacodynamics features [48] .
Ustekinumab is a fully human monoclonal antibody which blocks the activity of p40, a protein subunit shared by IL-12 and IL-23 [49, 50] . Ustekinumab demonstrated an extremely favorable safety profile as showed by a meta-analysis reporting that few adverse events associated with the use of etanercept and adalimumab reached statistical significance whereas no adverse events were significantly related to ustekinumab use [51] . Ustekinumab has been approved for the treatment of moderate to severe psoriasis in 2009 by the FDA; its efficacy and safety were assessed in the PHONENIX-1 and PHOENIX-2, double-bind, placebo-controlled, clinical trials through 5 years, in patients with moderate to severe plaque psoriasis [52, 53] . In addition to ustekinumab, briakinumab represents another anti-interleukin-12/23p40 monoclonal antibody [54] . Data on briakinumab are available in controlled phase II and III clinical trials, including two 52-week studies conducted in patients with psoriasis. In these studies, briakinumab treatment resulted in clinically significant improvements in quality of life and work productivity in adults with moderate to severe psoriasis [55] .
In another phase III, 12-week study, briakinumab showed higher efficacy when compared to placebo and etanercept in patients with moderate to severe chronic plaque psoriasis [56] .
Guselkumab (CNTO 1959, Centocor-Janssen Biotech) is a humanized IgG1 monoclonal antibody targeting IL-23p19 subunit that is now being tested in Phase III clinical trial [57] . Its use has been under investigation for the treatment of palmoplantar pustulosis in a Phase III clinical trial, whereas a Phase I trial evaluating the pharmacokinetic of guselkumab comparing lyophilized and liquid formulations has recently been completed (Table 1) .
In a randomized, double-blind, placebo-controlled study evaluating the safety, tolerability, and clinical response of guselkumab, IL-23 inhibition with a single dose of guselkumab resulted in clinical responses in patients with moderate-to-severe psoriasis, suggesting that neutralization of IL-23 alone is a promising therapy for psoriasis [58] .
Tildrakizumab is a high-affinity, humanized, IgG1/º , anti-IL-23p19 monoclonal antibody developed for treatment of chronic plaque psoriasis [59] . The safety and efficacy of subcutaneous tildrakizumab has been evaluated in a 3-part, randomized, double-blind, phase II trial conducted in 355 adult subjects with moderate to severe chronic plaque psoriasis [60] . Enrolled subjects received tildrakizumab ( 
Agents targeting IL-17 (secukinumab, brodalumab and ixekizumab)
Th-17 responses include the dysregulation of several cytokines, in particular IL-17A
that shows to have a key role in the regulation of innate and adaptive immune pathways [63] [64] [65] .
IL-17A is an inflammatory cytokine produced by a wide array of immune cells, Other clinical trials and subanalyses confirmed the preliminary data about safety and efficacy of secukinumab both in the short-and long-term [75] [76] [77] [78] [79] .
Brodalumab (AMG-827) is a fully human IgG2, monoclonal antibody that binds with high affinity IL17AR blocking IL-17A, IL-17E and IL-17F signaling. Clinical trials have been completed in rheumatoid arthritis, Crohn's disease and psoriasis [80, 81] . In a Phase III study of patients with moderate-to-severe plaque psoriasis, brodalumab was investigated versus ustekinumab and versus placebo [82] . Eighty-six percent of the patients in the brodalumab 210 mg group achieved at least 75% improvement in disease severity compared to baseline after 12 weeks, whereas 70% of patients in the ustekinumab arm and 8.1% of patients in the placebo arm achieved 75% improvement [82] . However, based on reports of suicidal thoughts and behavior during clinical trials, brodalumab development has been halted and a re-evaluation of the safety profile is being processed in order to rule out these safety warnings.
Ixekizumab (LY-2439821) is a IgG4 humanized anti-IL17 monoclonal antibody, which has been evaluated in a phase II, double-blind, placebo-controlled trial involving patients with chronic plaque psoriasis with scores of at least 12 on PASI [83, 84] . [84] . Recently, ixekizumab received the approval for the treatment of moderate-to-severe plaque psoriasis by FDA.
Bi-specific monoclonal antibodies
Conventionally, therapeutic monoclonal antibodies selectively recognize one target.
Because psoriasis pathogenesis identified multiple mediators playing a crucial role, novel therapeutics targeting more than one mediator could be more effective [85] .
Inflammation is one of the histopathological aspects characterizing psoriasis together with epidermal hyperplasia and neoangiogenesis, thus the neutralization of two targets at the same time may exclusively affect the inflammatory process as occurs blocking both IL-17 and TNF±, or blocking both vascular endothelial growth factor (VEGF) and TNF±, the inhibition of neoangiogenesis and inflammation may be induced.
Fynomers are small binding proteins (7 kDa) derived from the human Fyn SH3
domain. Fyn is a tyrosine-specific phospho-transferase that is a member of the Src family of tyrosine protein kinases Fynomers can be engineered to bind to any target of interest with high affinity and specificity [86, 87] . In a study published in 2014 a fynomer inhibiting in vitro IL-17A was developed (Fynomer 2C1) [88] . Recently, a novel drug called Valpha, which is a chimeric fusion protein inhibiting both VEGF and TNF± simultaneously, has been tested in a mouse model of psoriasis [90] . Valpha showed superior relief effects in a psoriasis model with regard to epidermal thickness and the area of blood and lymphatic vessels. Thus, the simultaneous blocking of VEGF-A and TNF± using Valpha could be an effective therapeutic strategy for psoriasis [91] .
Together with TNF±, another cytokine, namely IL-17A, is recognized as central to the development and progression of inflammatory diseases. Therapeutics, which are able to simultaneously inhibit TNF± and IL-17A, represent the next generation of biologic agents and they are expected to be more effective than current monospecific therapies.
The FynomAb COVA322 (Covagen Pharmaceuticals) is one of them. It consists of a fully human, clinically validated anti-TNF± antibody and anti-IL-17A fynomers, genetically fused to C-terminal light-chains of the antibody [92] . COVA322 inhibits with picomolar potency TNF± and IL-17A at the same time. COVA322 is currently under investigation in a Phase Ib/IIa clinical trial in patients with stable chronic moderate-to-severe plaque psoriasis (Table 1) .
Other targets
Itolizumab is a novel humanized monoclonal antibody which targets CD6, a T-cell costimulator molecule, involved in T cells proliferation, signaling, gene expression and cytokines secretion [93, 94] .
Itolizumab resulted effective and safe for the treatment of moderate-to-severe chronic plaque psoriasis, in a 52-week phase III, double-blind, randomized, placebocontrolled, parallel-arm, multicenter clinical trial, performed in twenty centers across India [95] . Two-hundred and twenty-two patients were randomized (2:2:1) to two different itolizumab arms A or B. The arm A received a 4-week loading dose of 0.4 mg/kg/wk followed by 1.6 mg/kg every 2 weeks. The arm B received 1.6/mg every 2 weeks. The arm C received placebo. At week 12, the placebo arm was switched to 1.6 mg/kg itolizumab every 2 weeks. The primary end point was the proportion of patients with at least 75% improvement in PASI score at week 12 [95] . The main secondary assessment was PGA. Quality-of-life assessments were also performed, using SF-36 and DLQI. Histopathology was evaluated: T-cell infiltration, rete thickness, and epidermal thickness in psoriatic lesions were measured. T cells were visualized in 7-to 8-µm sections using antihuman CD3 staining. One-hundred and ninety-nine patients (88.4%) completed week 28 and one-hundred and seventy-one patients (76.0%) completed the entire study (until week 52). Other than PASI score less than 50 at week 28, the common reasons for withdrawal were lost to follow-up (10 [4.4%]), withdrawal of consent (7 [3.1%]), and disease progression or relapse (7 [3.1%]). Five patients (2.2%) withdrew for adverse events (mostly, infusion reactions) [95] . A total of 27.0% in arm A, 36.4% in arm B, and 2.3% in arm C met the primary end point (achieved a PASI75 response at week 12) [95] . The difference from placebo was statistically significant (P = .0172 for A and .0043 for B). The induction regimen (arm A) did not demonstrate additional benefit. Improvement was seen in arm C after crossover to itolizumab at week 12 [95] . Responders continued to increase in arms A and B from week 12 to week 28. Improvements over placebo were seen for T-cell infiltration and epidermal thickness at week 12, and in all arms at week 28.
Itolizumab showed comparable efficacy to existing therapies, excellent safety, and measurable improvements in quality of life [95] .
Conclusion
Psoriasis is a debilitating disorder whose treatment has been profoundly modified by receptors will represent part of the future therapeutic armamentarium that will be completed by small molecule drugs.
Expert opinion
Psoriasis vulgaris is a chronic condition wherein effective and safe therapies are static Physician Global Assessment (sPGA), compared to ustekinumab [97] . Limited long-term clinical data for certain drugs, and the complete lack of clinical outcomes for the bispecific biologic agents, do not allow the definition of the future therapeutic paradigm. Likely, the introduction of IL-17 blockers will increase the opportunity to treat patients, providing an important chance not only for biologic-naïve patients, but also to those unresponsive to the current biologic drugs. To the light of recent and forthcoming approvals for various therapeutics, including apremilast, tildrakizumab, and guselkumab, and considering the future bispecific molecules approaching a later phase of development, the traditional therapeutic algorithm will profoundly change and it is difficult, now, to be defined.
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